|

Mitoxantrone liposome Clinical Trials

3 actively recruiting trials

▲ +1 trial since May 2026

Also known as: Mitoxantrone Hydrochloride Liposome Injection

Pipeline

Phase 2: 1Phase 1/2: 2

Top Sponsors

  • Hui Zeng1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
  • Beijing Tongren Hospital1

Indications

  • Cancer3
  • Hemophagocytic Lymphohistiocytosis (HLH)1
  • Adolescents1
  • Children1
  • Relapsed or Refractory Acute Myeloid Leukemia1

Other3 trials

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Phase 2
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Phase 1/2
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.